NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Forecast, Price & News

$0.90

+0.05 (+5.91%)

(As of 06/2/2023 ET)

Compare

Today's Range: $0.83
▼
$0.90
50-Day Range: $0.72
▼
$1.48
52-Week Range: $0.72
▼
$2.12

Volume: 126,746 shs
Average Volume: 566,668 shs
Market Capitalization: $73.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Pieris Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.24% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.57
Upright™ Environmental Score
News Sentiment: 1.00
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$8,500 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.71) to ($0.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

442nd out of 983 stocks

Pharmaceutical Preparations Industry

213th out of 486 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Pieris Pharmaceuticals.

4.0

Short Interest

Percentage of Shares Shorted
2.24% of the outstanding shares of Pieris Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Pieris Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pieris Pharmaceuticals has recently decreased by 1.08%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Pieris Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Pieris Pharmaceuticals does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pieris Pharmaceuticals has received a 76.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Pieris Pharmaceuticals is -0.57.

2.8

News and Social Media Coverage

News Sentiment
Pieris Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Pieris Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for PIRS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Pieris Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pieris Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Pieris Pharmaceuticals is held by insiders.
Percentage Held by Institutions
47.31% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Pieris Pharmaceuticals are expected to grow in the coming year, from ($0.71) to ($0.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pieris Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pieris Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pieris Pharmaceuticals has a P/B Ratio of 4.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pieris Pharmaceuticals (NASDAQ:PIRS) Stock

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

June 2, 2023 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference

June 2, 2023 | finance.yahoo.com

Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference

June 2, 2023 | UNKNOWN (Ad)

This NASDAQ Stock Is The Amazon Of Medical Supply

This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now

May 22, 2023 | finance.yahoo.com

Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference

May 21, 2023 | finance.yahoo.com

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

May 17, 2023 | americanbankingnews.com

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to Post Q2 2023 Earnings of ($0.16) Per Share, William Blair Forecasts

May 15, 2023 | finance.yahoo.com

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially

May 12, 2023 | seekingalpha.com

Pieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, revenue of $1.94M misses by $4.57M

June 2, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 11, 2023 | finance.yahoo.com

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript

May 10, 2023 | msn.com

Recap: Pieris Pharmaceuticals Q1 Earnings

May 10, 2023 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates

May 10, 2023 | finance.yahoo.com

Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates

May 9, 2023 | msn.com

Preview: Pieris Pharmaceuticals's Earnings

May 8, 2023 | americanbankingnews.com

Pieris Pharmaceuticals (PIRS) to Release Quarterly Earnings on Tuesday

May 5, 2023 | finance.yahoo.com

Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The Business

May 4, 2023 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep

May 4, 2023 | finance.yahoo.com

Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)

May 2, 2023 | finance.yahoo.com

Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023

April 17, 2023 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa At 2023 AACR Annual Meeting

April 17, 2023 | finance.yahoo.com

Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting

April 5, 2023 | americanbankingnews.com

William Blair Comments on Pieris Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:PIRS)

April 4, 2023 | americanbankingnews.com

Pieris Pharmaceuticals, Inc. Forecasted to Post Q1 2023 Earnings of ($0.19) Per Share (NASDAQ:PIRS)

April 2, 2023 | americanbankingnews.com

Equities Analysts Set Expectations for Pieris Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:PIRS)

April 1, 2023 | finance.yahoo.com

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript

March 31, 2023 | finance.yahoo.com

Pieris Pharmaceuticals Full Year 2022 Earnings: US$0.45 loss per share (vs US$0.71 loss in FY 2021)

March 31, 2023 | americanbankingnews.com

Jefferies Financial Group Comments on Pieris Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:PIRS)

See More Headlines

PIRS Price History

30 days | 90 days | 365 days | Advanced Chart

PIRS Company Calendar

Last Earnings: 3/29/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PIRS
CUSIP: N/A
CIK: 1583648
Web: www.pieris.com
Phone: (857) 246-8998
Fax: 49-8161-141-1444
Employees: 124
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,280,000.00
Net Margins: -245.45%
Pretax Margin: -245.45%
Return on Equity: -133.94%
Return on Assets: -42.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.41
Quick Ratio: 1.41

Sales & Book Value

Annual Sales: $25.90 million
Price / Sales: 2.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.19 per share
Price / Book: 4.47

Miscellaneous

Outstanding Shares: 82,020,000
Free Float: 76,032,000
Market Cap: $69.73 million
Optionable: Optionable
Beta: 1.08

Key Executives

Stephen S. Yoder
President, Chief Executive Officer & Director

Thomas Bures
Senior VP, Chief Financial & Accounting Officer

Kayti Aviano
Vice President-Clinical Operations

Hitto Kaufmann
Chief Scientific Officer & Senior Vice President

Shane Olwill
Chief Development Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PIRS Stock - Frequently Asked Questions

How have PIRS shares performed in 2023?: Pieris Pharmaceuticals' stock was trading at $1.04 on January 1st, 2023. Since then, PIRS shares have decreased by 18.3% and is now trading at $0.8501.
View the best growth stocks for 2023 here.
When is Pieris Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PIRS earnings forecast.
How were Pieris Pharmaceuticals' earnings last quarter?: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its quarterly earnings results on Wednesday, March, 29th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The biotechnology company had revenue of $5.85 million for the quarter, compared to analysts' expectations of $6.51 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 133.94% and a negative net margin of 245.45%.
What other stocks do shareholders of Pieris Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL).
What is Pieris Pharmaceuticals' stock symbol?: Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?: Pieris Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.63%), Platinum Investment Management Ltd. (1.31%), Acadian Asset Management LLC (0.85%), Renaissance Technologies LLC (0.52%), Candriam S.C.A. (0.47%) and Affinity Asset Advisors LLC (0.37%). Insiders that own company stock include Aquilo Capital Management, Llc, Christopher P Kiritsy, Shane Olwill and Tim Demuth.
View institutional ownership trends.
How do I buy shares of Pieris Pharmaceuticals?: Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pieris Pharmaceuticals' stock price today?: One share of PIRS stock can currently be purchased for approximately $0.85.
How much money does Pieris Pharmaceuticals make?: Pieris Pharmaceuticals (NASDAQ:PIRS) has a market capitalization of $69.73 million and generates $25.90 million in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.
How many employees does Pieris Pharmaceuticals have?: The company employs 124 workers across the globe.
How can I contact Pieris Pharmaceuticals?: Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The official website for the company is www.pieris.com. The biotechnology company can be reached via phone at (857) 246-8998, via email at kelman@pieris.com, or via fax at 49-8161-141-1444.

This page (NASDAQ:PIRS) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pieris Pharmaceuticals (PIRS) Stock Forecast, Price & News

Pieris Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™